nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2005-9-2-48-52nefr-745Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯORIGINAL ARTICLES. CLINICAL INVESTIGATIONSРАСПРОСТРАНЕННОСТЬ ГИПЕРГОМОЦИСТЕИНЕМИИ В ЗАВИСИМОСТИ ОТ СТАДИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕКINCIDENCE OF HYPERHOMOCYCTEINEMIA DEPENDING ON THE STAGE OF CHRONIC RENAL DISEASEСмирновА. В.SmirnovA. V.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

ДобронравовВ. А.DobronravovV. A.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

ГолубевР. В.GolubevR. V.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

ТрофименкоИ. И.TrofimenkoI. I.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

ПанинаИ. Ю.PaninaI. Yu.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

ЖлобаА. А.ZhlobaA. A.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

БлашкоЭ. Л.BlashkoE. L.

Кафедра пропедевтики внутренних болезней, отделение хронического гемодиализа, отдел биохимии научноисследовательского центра

Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербургский медико-технический институтRussian Federation200510022005924852Copyright © Смирнов А.В., Добронравов В.А., Голубев Р.В., Трофименко И.И., Панина И.Ю., Жлоба А.А., Блашко Э.Л., 20052005Смирнов А.В., Добронравов В.А., Голубев Р.В., Трофименко И.И., Панина И.Ю., Жлоба А.А., Блашко Э.Л.Smirnov A.V., Dobronravov V.A., Golubev R.V., Trofimenko I.I., Panina I.Y., Zhloba A.A., Blashko E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/745

ЦЕЛЬ ИССЛЕДОВАНИЯ. Исследование уровня гомоцистеина плазмы у больных на разных стадиях хронической болезни почек (ХБП). ПАЦИЕНТЫ И МЕТОДЫ. Методом высокоэффективной жидкостной хроматографии определен уровень обще го гомоцистеина (Hcy) плазмы у 219 больных с разными стадиями ХБП, из них 125 больных на додиализном этапе и 94 больных, получающих лечение хроническим бикарбонатным гемодиализом. РЕЗУЛЬТАТЫ. Распространенность гипергомоцистеинемии высока уже на начальных стадиях ХБП и увеличивается по мере снижения СКФ, достигая максимума в группе диализных больных. Выявлена обратная зависимость между величиной СКФ и уровнем Нсу плазмы в группе больных, не получающих диализного лечения. ЗАКЛЮЧЕНИЕ. Повышение уровня гомоцистеина плазмы отмечается, начиная с ранних стадий ХБП, и достигает максимально высоких значений и встречаемости у пациентов, получающих терапию гемодиализом.

THE AIM of the investigation was to study the level of plasma homocysteine in patients at different stages of chronic renal disease (CRD). PATIENTS AND METHODS. The level of plasma homocysteine (HCy) was determined by the method of highly effective liquid chromatography in 219 patients with different stages of CRD, 125 of the patients were at the predialysis stage and 94 patients were treated by chronic bicarbonate hemodialysis. RESULTS. The incidence of hyperhomocysteinemia was high as early as at the initial stages of CRD and was increasing along with decreasing GFR and reached the maximum in the group of dialysis patients. An inverse dependence was revealed between the GFR and the plasma HCy level in the group of patients not given dialysis treatment. CONCLUSION. An increased level of plasma homocysteine is noted beginning from the early stages of CRD and reaches the maximally high values and incidence in patients treated by hemodialysis.

гомоцистеингипергомоцистеинемияпочечная недостаточностьхроническая болезнь почекгемодиализhomocysteinehyperhomocysteinemiarenal failurechronic renal diseasehemodialysisReferencesFoley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [ Suppl 3]: S112S119Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [ Suppl 3]: S112S119Friedman AN, Bostom AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181 2189Friedman AN, Bostom AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181 2189McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA 1998; 279 (5): 392393McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA 1998; 279 (5): 392393Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274 (13): 10491057Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274 (13): 10491057Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 17751781Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 17751781Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland homocysteine study. Am J Clin Nutr 2001; 74(1): 130 – 136Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland homocysteine study. Am J Clin Nutr 2001; 74(1): 130 – 136Hoogeveen EK, Kostense PJ, Jakobs C et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5year followup of the hoorn dtudy. Circulation 2000; 101(13): 1506 – 1511Hoogeveen EK, Kostense PJ, Jakobs C et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5year followup of the hoorn dtudy. Circulation 2000; 101(13): 1506 – 1511Jungers P, Chauveau P, Bandin O et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 1997; 23 : 170173Jungers P, Chauveau P, Bandin O et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 1997; 23 : 170173Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 27432748;Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 27432748;Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in endstage renal disease. Circulation 1998; 97:138 141;Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in endstage renal disease. Circulation 1998; 97:138 141;Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997;17: 25542558Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997;17: 25542558Levey AS, Borsch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine a new prediction indication. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 471 482Levey AS, Borsch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine a new prediction indication. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 471 482K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1266K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1266Zhloba AA, Blashko EL. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800 (12): 275280Zhloba AA, Blashko EL. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800 (12): 275280Francis ME, Eggers P W, Hostetter T H, Briggs J P. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004; 66 (1): 303312Francis ME, Eggers P W, Hostetter T H, Briggs J P. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004; 66 (1): 303312Arnadottir M, Hultberg B, NilssonEhle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56 (1): 4146Arnadottir M, Hultberg B, NilssonEhle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56 (1): 4146Wollesen F, Brattstrom L, Refsum H et al. Plasma total homocysteine and cysteine in relation to GFR in diabetes mellitus. Kidney Int 1999; 55 (3): 10281035Wollesen F, Brattstrom L, Refsum H et al. Plasma total homocysteine and cysteine in relation to GFR in diabetes mellitus. Kidney Int 1999; 55 (3): 10281035Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 1020Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 1020Culleton BF, Bostom AG. Hyperhomocysteinemia in chronic renal disease. In: Loscalzo J, London GM (eds.) Cardiovascular disease in end stage renal failure. New York: Oxford university press; 2000: 211228Culleton BF, Bostom AG. Hyperhomocysteinemia in chronic renal disease. In: Loscalzo J, London GM (eds.) Cardiovascular disease in end stage renal failure. New York: Oxford university press; 2000: 211228Rosenthal AF, Ginsberg MJ, Crawford JF. Homocysteine and heart disease in dialysis patients. Dial Transplant 1998; 27 (10): 627630Rosenthal AF, Ginsberg MJ, Crawford JF. Homocysteine and heart disease in dialysis patients. Dial Transplant 1998; 27 (10): 627630Bostom AG, Shemin D, Lapane KL et al. High dose B vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49 (1): 147152Bostom AG, Shemin D, Lapane KL et al. High dose B vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49 (1): 147152van Guldener C, Janssen MJFM, Lambert J et al. No change in impaired endothelial function after longterm folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106112van Guldener C, Janssen MJFM, Lambert J et al. No change in impaired endothelial function after longterm folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106112den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta analysis. Thromb Haemost 1998; 80: 8747den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta analysis. Thromb Haemost 1998; 80: 8747Ray JG. Metaanalysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 21012106Ray JG. Metaanalysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 21012106Shemin D, Lapane KL, Bausserman L et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999; 10: 10951099Shemin D, Lapane KL, Bausserman L et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999; 10: 10951099Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 2004; 44(3): 43745Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 2004; 44(3): 43745Смирнов АВ, Жлоба АА, Барабанова ВВ и др. Ги пергомоцистеинемия как фактор повреждения почек. Нефрология 2004; 8 [прил 2]: 284.Смирнов АВ, Жлоба АА, Барабанова ВВ и др. Ги пергомоцистеинемия как фактор повреждения почек. Нефрология 2004; 8 [прил 2]: 284.Kumagai H, Katoh S, Hirosawa K et al. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62: 12191228;Kumagai H, Katoh S, Hirosawa K et al. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62: 12191228;Li N, Chen Y, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002; 39: 443448;Li N, Chen Y, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002; 39: 443448;Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma in urine. Clin Chem 1985; 31: 624628Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma in urine. Clin Chem 1985; 31: 624628Foreman JW, Wald H, Blumberg G et al. Homocystine uptake in isolated rat renal cortical tubules. Metabolism 1982; 31: 613–619Foreman JW, Wald H, Blumberg G et al. Homocystine uptake in isolated rat renal cortical tubules. Metabolism 1982; 31: 613–619Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217–246Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217–246Gaull GE, von Berg W, Raiha NCR, Sturman JA. Development of methyltransferase activities of human fetal tissues. Pediatr Res 1973; 7: 527–533Gaull GE, von Berg W, Raiha NCR, Sturman JA. Development of methyltransferase activities of human fetal tissues. Pediatr Res 1973; 7: 527–533Bao L, Vlcek C, Paces V, Kraus JP. Identification and tissue distribution of human cystathionine Іsynthase mRNA isoforms. Arch Biochem Biophys 1998; 350: 95–103Bao L, Vlcek C, Paces V, Kraus JP. Identification and tissue distribution of human cystathionine Іsynthase mRNA isoforms. Arch Biochem Biophys 1998; 350: 95–103Sturman JA, Rassin DK, Gaull GE. Distribution of transulphuration enzymes in various organs and species. Int J Biochem 1970; 1: 251253Sturman JA, Rassin DK, Gaull GE. Distribution of transulphuration enzymes in various organs and species. Int J Biochem 1970; 1: 251253van Guldener C, Donker AJM, Jakobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54 (1): 166169van Guldener C, Donker AJM, Jakobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54 (1): 166169Fowler B. The folate cycle and disease in humans. Kidney Int 2001; 59 [Suppl 78]: 221229Fowler B. The folate cycle and disease in humans. Kidney Int 2001; 59 [Suppl 78]: 221229Massy Z A. Reversal of hyperhomocyst(e)inaemia in chronic renal failure—is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14: 28102812Massy Z A. Reversal of hyperhomocyst(e)inaemia in chronic renal failure—is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14: 28102812van Guldener C, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56 (3): 10641071van Guldener C, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56 (3): 10641071Stam F, van Guldener C, ter Wee PM et al. Effect of folic acid on methionine and homocysteine metabolism in endstage renal disease. Kidney Int 2005; 67(1): 259264Stam F, van Guldener C, ter Wee PM et al. Effect of folic acid on methionine and homocysteine metabolism in endstage renal disease. Kidney Int 2005; 67(1): 259264Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40(4): 230 235Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40(4): 230 235van Guldener C, Janssen MJFM, de Meer K et al. Effect of folic acid and betaine on fasting and postmethionineloading plasma homocysteine and methionine levels in chronic hemodialysis patients. J Int Med 1999; 245: 175183van Guldener C, Janssen MJFM, de Meer K et al. Effect of folic acid and betaine on fasting and postmethionineloading plasma homocysteine and methionine levels in chronic hemodialysis patients. J Int Med 1999; 245: 175183Fodinger M, Wagner OF, Horl WH, SunderPlassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001; 59 (S78): S238 242Fodinger M, Wagner OF, Horl WH, SunderPlassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001; 59 (S78): S238 242Fodinger M, Buchmayer 1 H, Heinz G et al. Effect of MTHFR 1298AC and MTHFR677CT genotypes on total homocysteine, folate, and vitamin B12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol 2000; 11(10): 1918 1925Fodinger M, Buchmayer 1 H, Heinz G et al. Effect of MTHFR 1298AC and MTHFR677CT genotypes on total homocysteine, folate, and vitamin B12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol 2000; 11(10): 1918 1925SunderPlassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int 2003; 63 (s84): 141144SunderPlassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int 2003; 63 (s84): 141144Feix A, FritschePolanz Rt, Kletzmayr J et al. Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis 2001; 38 (5): 956 – 964Feix A, FritschePolanz Rt, Kletzmayr J et al. Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis 2001; 38 (5): 956 – 964Tsai MY, Garg U, Key NS et al. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996; 122: 6977Tsai MY, Garg U, Key NS et al. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996; 122: 6977Gaustadnes M, Rudiger N, Rasmussen K et al. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost 2000; 83: 554558Gaustadnes M, Rudiger N, Rasmussen K et al. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost 2000; 83: 554558de Franchis R, Fermo I, Mazzola G et al. Contribution of the cystathionine betasynthase gene (844ins68) polymorphism to the risk of earlyonset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 57682de Franchis R, Fermo I, Mazzola G et al. Contribution of the cystathionine betasynthase gene (844ins68) polymorphism to the risk of earlyonset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 57682Добронравов ВА, Ларионова ВИ, Смирнов АВ и др. Подходы к анализу роли молекулярногенетических и средовых факторов в развитии сердечнососудистой патологии у больных на диализе. Нефрология 2003; 7 [Прил. 1]: 2931Добронравов ВА, Ларионова ВИ, Смирнов АВ и др. Подходы к анализу роли молекулярногенетических и средовых факторов в развитии сердечнососудистой патологии у больных на диализе. Нефрология 2003; 7 [Прил. 1]: 2931

The authors declare that there are no conflicts of interest present.